ArticlePharmacoEconomics - open2019

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK.

Claire Telford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.